Release Summary

Updated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA (pembrolizumab) Demonstrate Clinical Activity Across Multiple Tumor Types

Incyte Corporation and Merck